PLUS1
0.7145
0.0293 (4.28%)
0.0293 (4.28%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Onconova Therapeutics Inc | ONTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.0293 | 4.28% | 0.7145 | 19:57:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.7005 | 0.6898 | 0.74 | 0.70 | 0.6852 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.7106 | 0.7145 | 0.0039 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 22,050 | 16,563,388 | $ 0.7115061 | $ 11,784,952 | 40,698,924 | 0.1901 - 1.56 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:29 | 1 | $ 0.7145 | USD |
Onconova Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 133.71M | 187.14M | 205.72M | $ 2.18M | $ - | -1.50 | 0.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Onconova Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/15/2021 | 17:15 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/14/2021 | 08:00 | GlobeNewswire Inc. | Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual.. |
| 1/13/2021 | 16:16 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
| 1/08/2021 | 16:39 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 1/08/2021 | 16:11 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 1/08/2021 | 09:11 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/07/2021 | 09:40 | GlobeNewswire Inc. | Onconova Therapeutics, Inc. Announces $8.7 Million Public.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.805 | 0.838 | 0.681 | 0.7412201 | 24,197,790 | -0.0905 | -11.24% |
| 1 Month | 0.4551 | 0.949 | 0.418 | 0.7239084 | 44,835,175 | 0.2594 | 57.0% |
| 3 Months | 0.2532 | 0.949 | 0.24 | 0.5661965 | 27,934,214 | 0.4613 | 182.19% |
| 6 Months | 1.25 | 1.38 | 0.1901 | 0.5176189 | 21,753,977 | -0.5355 | -42.84% |
| 1 Year | 0.365 | 1.56 | 0.1901 | 0.5426892 | 17,675,190 | 0.3495 | 95.75% |
| 3 Years | 23.70 | 24.408 | 0.1027 | 0.8372107 | 7,762,262 | -22.99 | -96.99% |
| 5 Years | 9.75 | 122.55 | 0.1027 | 1.23 | 4,720,476 | -9.04 | -92.67% |
Onconova Therapeutics Description
| Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. |
